Literature DB >> 9597680

Quality of life in patients with low-grade non-Hodgkin's lymphoma.

K Webster1, D Cella.   

Abstract

Low-grade non-Hodgkin's lymphoma (NHL) is an indolent form of the disease with a generally slow course of progression. Although still usually incurable, low-grade disease has shown responsiveness to some of the newer chemotherapeutic and nonchemotherapeutic treatment options. However, since cure remains elusive, and since many patients with lowgrade NHL may have few or even no symptoms initially, the decision about whether or not to initiate treatment logically must include quality-of-life (QOL) issues. This paper summarizes clinical and diagnostic characteristics of low-grade NHL that have some bearing on QOL considerations. Adverse effects of the more common treatment approaches are discussed according to their QOL implications, illustrating the relevance of QOL to the clinical management of low-grade disease. Finally, data from an ongoing study using the Functional Assessment of Cancer Therapy (FACT) measurement system are presented. These data offer a basis for comparing the QOL of patients with NHL to that of individuals with other solid tumors, and also illustrate the effects of chemotherapy on QOL.

Entities:  

Mesh:

Year:  1998        PMID: 9597680

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  11 in total

Review 1.  Aggressive non-Hodgkin's lymphoma: economics of high-dose therapy.

Authors:  Stephen M Beard; Lucy Wall; Louise Gaffney; Fiona Sampson
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 2.  Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Authors:  Risto S Cvetković; Caroline M Perry
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis.

Authors:  Rebecca L Olin; Peter A Kanetsky; Thomas R Ten Have; Sunita D Nasta; Stephen J Schuster; Charalambos Andreadis
Journal:  Am J Hematol       Date:  2010-04       Impact factor: 10.047

4.  A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy - Lymphoma Symptom Index.

Authors:  Fay J Hlubocky; Kimberly Webster; Jennifer Beaumont; John Cashy; Diane Paul; Amy Abernethy; Karen L Syrjala; Jamie Von Roenn; David Cella
Journal:  Leuk Lymphoma       Date:  2013-02-07

5.  Symptom Burden and Quality of Life in Patients with Follicular Lymphoma undergoing Maintenance Treatment with Rituximab Compared with Observation.

Authors:  Mark S Walker; Edward J Stepanski; Carolina Reyes; Sacha Satram-Hoang; Arthur C Houts; Lee S Schwartzberg
Journal:  Ther Adv Hematol       Date:  2011-06

6.  Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402.

Authors:  Brad S Kahl; Fangxin Hong; Michael E Williams; Randy D Gascoyne; Lynne I Wagner; John C Krauss; Thomas M Habermann; Lode J Swinnen; Stephen J Schuster; Christopher G Peterson; Mark D Sborov; S Eric Martin; Matthias Weiss; W Christopher Ehmann; Sandra J Horning
Journal:  J Clin Oncol       Date:  2014-08-25       Impact factor: 44.544

Review 7.  Follicular lymphoma: management options in the era of targeted therapy.

Authors:  Christopher G Peterson; Brad S Kahl
Journal:  Curr Treat Options Oncol       Date:  2005-07

8.  Factors affecting the quality of life of cancer patients undergoing chemotherapy: A questionnaire study.

Authors:  Sema Üstündağ; Ayten Demir Zencirci
Journal:  Asia Pac J Oncol Nurs       Date:  2015 Jan-Mar

Review 9.  Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Authors:  Greg L Plosker; David P Figgitt
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Cost-Utility Analysis of IEV Drug Regimen Versus ESHAP Drug Regimen for the Patients With Relapsed and Refractory Hodgkin and Non-Hodgkin's Lymphoma in Iran.

Authors:  Nahid Hatam; Mehdi Dehghani; Mostafa Habibian; Abdosaleh Jafari
Journal:  Iran J Cancer Prev       Date:  2015-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.